The cover story of last week’s Time magazine wasn’t the usual fare, such as “Marco Rubio: Savior of the Republican Party.”
“Bitter Pill: Why Medical Bills Are Killing Us” is a serious, exhaustively reported piece about the scam the U.S. health-care system has become. The article, by Steven Brill, has created unusual buzz in Washington; it spares no vested interest.
Nonprofit hospitals, the cornerstone of many communities, capriciously overcharge patients, sticking the powerless with exorbitant bills while paying lavish salaries to their executives. Drug companies, which charge humongous markups to American customers, rake in huge profits. Trial lawyers, with the threat of legal action, add to the cost of defensive medicine. President Obama’s Affordable Care Act does little to bend the cost curve, and while conservatives rail against Medicare, the government-run program is more efficient and customer-friendly than the private system.
None of this is new. Yet it resonates for several reasons: Brill documents the particulars more forcefully, and, as health- care spending approaches 20 percent of the U.S. economy, almost every American is affected and the debate is politically polarizing.
When asked to respond to these charges, most of the system’s stakeholders react in similar ways: Many of these criticisms are valid — except when it applies to us.
The American Hospital Association says, yes, the current billing system is broken, but hospitals aren’t to blame. When patients look at hospital bills, says Richard Umbdenstock, the group’s president, the prices reflect not just the cost of a particular item but “all the resources required to provide the care.” Moreover, he says, the “vast majority” of patients don’t pay the initial bill; that’s just the starting point.
Linda Lipsen, chief executive officer of the American Association for Justice, which represents trial lawyers, said in an interview that Brill’s article correctly focuses on health- care costs. Brill opposes the limits on malpractice suits advocated by some conservatives. Yet Lipsen takes issue with his more moderate call for a “safe harbor” standard that would require a defendant — a hospital or a doctor — to demonstrate that care was within the bounds of accepted medical practice.
“This would preclude some people who’re injured or killed being able to get to court,” Lipsen says. “Each case has its individual practices.”
The pharmaceutical industry insists that drugs account for less than 10 percent of health-care costs, are rising at a slow clip and that bargaining by big-bulk purchasers creates a genuine market system.
The administration argues that the Affordable Care Act will significantly reduce costs; Republicans on Capitol Hill dismiss the arguments in Medicare’s favor.
If all this were true, the system would be fine. It isn’t. Three-fifths of U.S. bankruptcies are caused by medical bills. There is little procedure or price transparency; it’s difficult to check a physician’s record or the performance of drugs and treatments.
Pharmaceutical and medical-device companies, according to Brill, “regularly put clauses in sales contracts prohibiting hospitals from sharing information about what they pay and discounts they get.”
- A woman enters a Connecticut hospital with chest pains. She is examined and is released after four hours once it has been determined there is nothing wrong. The bill: $21,000.
- A monthlong stay in a Dallas hospital for treatment of pneumonia cost more than $474,000, less than 20 percent of which was covered by insurance.
- The CEOs of hospitals affiliated with universities make three times more than the president of their university systems.
- Medical device makers, who are angry about the small tax imposed by Obamacare, are producing returns of 15 percent or more. So are drug companies that charge about a 50 percent premium to patients in the U.S.
- Medicare is prohibited by Congress from using its leverage to bargain for better prescription-drug prices or to use “comparative effectiveness” tests in approving drugs or procedures.
The trial lawyers are right that the impact of malpractice suits is exaggerated; Texas has enacted one of the toughest limits on them and it hasn’t really driven down overall costs. In fact, the threat of litigation is often used as an excuse to perform profitable procedures. Still, something like the safe harbor standard could make some difference and eliminate a distracting argument.
Medicare gets whacked a lot these days by politicians. Brill demonstrates that the program is more cost-effective. Rather than raising the eligibility age for benefits, he says, lowering the age limit and allowing more people to qualify would decrease health-care costs.
Obama’s health-care law guarantees that a lot more Americans will have health insurance — a good thing — but the administration is on shakier ground when it contends that the measure will curb costs.
Overall, the system is predicated on a nebulous assumption that there is a real marketplace affected by supply and demand. That’s largely a myth. Consuming health care isn’t the same as purchasing shoes or a car: If you go to the emergency room or are diagnosed with cancer, you’re not likely to bargain-shop.
The system’s big stakeholders have well-connected lobbyists, are important campaign contributors or forces in their communities.
They react to articles such as Brill’s, but really aren’t much worried. They are rich, powerful and protected.
Albert R. Hunt is a Bloomberg View columnist.